The iR(2) regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study
iR(2)方案(伊布替尼联合来那度胺和利妥昔单抗)治疗复发/难治性弥漫性大B细胞淋巴瘤:一项多中心、非随机、开放标签的II期研究
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2022.101779
Ramchandren, Radhakrishnan; Johnson, Peter; Ghosh, Nilanjan; Ruan, Jia; Ardeshna, Kirit M; Johnson, Roderick; Verhoef, Gregor; Cunningham, David; de Vos, Sven; Kassam, Shireen; Fayad, Luis; Radford, John; Bailly, Sarah; Offner, Fritz; Morgan, David; Munoz, Javier; Ping, Jerry; Szafer-Glusman, Edith; Eckert, Karl; Neuenburg, Jutta K; Goy, Andre